Business
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease
WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo No difference in total HTT protein or
About this update from Wave Life Sciences Ltd.
[{"type":"text","content":"WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo\n No difference in total HTT protein or neurofilament light chain in treated patients vs. placebo Additional cohort expected to initiate in January 2020 Wave to host investor conference call and webcast at 8:00 a.m. ET today CAMBRIDGE, Mass., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced topline data from the ongoing Phase 1b/2a PRECISION-HD2 trial evaluating investigational therapy WVE-120102, designed to be the first allele-selective approach to treat Huntington’s disease (HD). In an analysis comparing all patients treated with multiple intrathecal doses of WVE-120102 to placebo, a statistically significant reduction of 12.4% (p","length":1292,"tagName":"div"}]